PDF herunterladen
ZFA (Stuttgart) 2004; 80(2): 77-81
DOI: 10.1055/s-2004-816225
Fortbildung

© Georg Thieme Verlag Stuttgart · New York

ASS für alle?

Aspirin for Everyone?S. Hensler1 , U. Popert1
  • 1Institut für Allgemeinmedizin der Universität Frankfurt a. M.
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
10. März 2004 (online)

    Lizenzen und Reprints

Zusammenfassung

Acetylsalicylsäure in einer Dosierung von 75-160 mg/Tag ist nachweisbar wirksam zur Primärprävention von Herzinfarkten und zur Sekundärprävention von Schlaganfällen. Unter der Beachtung von Gefahren durch Nebenwirkungen ist eine Behandlung nahezu immer sinnvoll in der Sekundärprävention nach Herzinfarkt, ischämischen Hirninsult und bei KHK. In der Primärprävention kann eine Behandlung ab 1-1,5 %/Jahr Gesamtrisiko für Gefäßereignisse empfohlen werden.

Abstract

Aspirin 75-160 mg/d is effective in primary prevention of myocardial infarction and secondary prevention of ischaemic stroke. Considering potential hazards of side-effects, treatment is almost always justified in secondary prevention after MI, stroke, or in CVD. In primary prevention, treatment can be recommended if overall CVD-risk exceeds 1-1.5 % per year.

Schlüsselwörter

ASS - Kardivaskuläre Prävention - Schlaganfall - Herzinfarkt

Key words

Aspirin - cardiovascular prevention - stroke - myocardial infarction

Literatur

  • 1 Anderson K M, Wilson P WF, Odell P M, Kannel W B. An updated coronary risk factor profile: a statement for health professionals.  Circulation. 1991;  83 356-362
    CrossrefPubMedGoogle Scholar
  • 2 Antithrombotic Trialists' Collaboration . Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.  BMJ. 2002;  324 71-86
    CrossrefPubMedGoogle Scholar
  • 3 Arzneimittelbrief . Absetzen von Azetylsalizylsäure vor Operationen.  Der Arzneimittelbrief. 2000;  34 56
    PubMedGoogle Scholar
  • 4 Arzneimittelbrief . Nochmals: Absetzen von Azetylsalizylsäure vor Operationen.  Der Arzneimittelbrief. 2000;  34 71-72
    PubMedGoogle Scholar
  • 5 Boissel J P. Individualizing aspirin therapy for prevention of cardiovascular events.  JAMA. 1998;  280 1949-1950
    CrossrefPubMedGoogle Scholar
  • 6 Borgers D. Universelle primärmedizinische Medikation des kardiovaskulären Risikos: ein WHO-Vorschlag.  Z Allg Med. 2003;  79 244-247
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 7 Bosetti C, Gallus S, La Vecchia C. Aspirin and cancer risk: an update to 2001.  Eur J Cancer Prev. 2002;  11 535-542
    PubMedGoogle Scholar
  • 8 Broe G A, Grayson D A, Creasey H M, Waite L M, Casey B J, Bennett H P. et al . Anti-inflammatory drugs protect against Alzheimer disease at low doses.  Arch Neurol. 2000;  57 1586-1591
    CrossrefPubMedGoogle Scholar
  • 9 CAPRIE Steering Committee . A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).  Lancet. 1996;  348 1329-1339
    CrossrefPubMedGoogle Scholar
  • 10 Corley D A, Kerlikowske K, Verma R, Buffler P. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis.  Gastroenterology. 2003;  124 47-56
    CrossrefPubMedGoogle Scholar
  • 11 D'Agostino R B, Russell M W, Huse D M, Ellison C, Silbershatz H, Wilson P W. et al . Primary and subsequent coronary risk appraisal: new results from the Framingham study.  Am Heart J. 2000;  139 272-281
    PubMedGoogle Scholar
  • 12 De Gaetano G.. Collaborative Group of the Primary Prevention Project . Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project.  Lancet. 2001;  357 89-95
    CrossrefPubMedGoogle Scholar
  • 13 De Schryver E L, Algra A, van Gijn J. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease (Cochrane Review). In: The Cochrane Library, Issue 1. Update Software, Oxford 2003
    Google Scholar
  • 14 Diener H C, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A.. European Stroke Prevention Study . 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.  J Neurol Sci. 1996;  143 1-13
    CrossrefPubMedGoogle Scholar
  • 15 Eccles M, Freemantle N, Mason J. North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care. North of England Aspirin Guideline Development Group.  BMJ. 1998;  316 1303-1309
    PubMedGoogle Scholar
  • 16 Elwood P C, Cochrane A L, Burr M L, Sweetnam P M, Williams G, Welsby E, Hughes S J, Renton R. A randomised controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction.  Br Med J. 1974;  1 436-440
    PubMedGoogle Scholar
  • 17 ETDRS Investigators . Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14.  JAMA. 1992;  268 1292-1300
    CrossrefPubMedGoogle Scholar
  • 18 Rote Liste .Fachinformation Azetylsalizylsäure (A5). Edition Cantor Verlag 2003, Aulendorf
    Google Scholar
  • 19 Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results.  J Neurol Neurosurg Psychiatry. 1991;  54 1044-1054
    CrossrefPubMedGoogle Scholar
  • 20 Flower R. What are all the things that aspirin does?.  BMJ. 2003;  327 572-573
    CrossrefPubMedGoogle Scholar
  • 21 Hankey G J, Warlow C P. Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations.  Lancet. 1999;  354 1457-1463
    CrossrefPubMedGoogle Scholar
  • 22 Hansson L, Zanchetti A, Carruthers S G, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn K H, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial.  HOT Study Group.  Lancet. 1998;  351 1755-1762
    CrossrefPubMedGoogle Scholar
  • 23 Hass W K, Easton J D, Adams H P, Pryse-Phillips W, Molony B A, Anderson S, Kamm B. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine.  Aspirin Stroke Study Group  N Engl J Med. 1989;  321 501-507
    CrossrefPubMedGoogle Scholar
  • 24 Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force.  Ann Intern Med. 2002;  136 161-172
    PubMedGoogle Scholar
  • 25 Heart Outcomes Prevention Evaluation Study Investigators . Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy.  Lancet. 2000;  355 253-259
    CrossrefPubMedGoogle Scholar
  • 26 Heart Protection Study Collaborative Group . MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial.  Lancet. 2002;  360 7-22
    CrossrefPubMedGoogle Scholar
  • 27 Hedman J, Kaprio J, Poussa T, Nieminen M M. Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study.  Int J Epidemiol. 1999;  28 717-722
    CrossrefPubMedGoogle Scholar
  • 28 Hoigne R V, Braunschweig S, Zehnder D, Kuenzi U P, Hess T, Leuenberger P. Drug-induced attack of bronchial asthma in inpatients: a 20-year-survey of the Comprehensive Hospital Drug Monitoring Programme on adverse drug reactions, Berne/St. Gallen.  Eur J Clin Pharmacol. 1997;  53 81-82
    CrossrefPubMedGoogle Scholar
  • 29 Homepage der Firma Bayer (besucht am 30.10.2003) .http://www.aspirin.com/world_of_aspirin_de.html
  • 30 ISIS-2 (Second International Study of Infarct Survival) Collaborative Group . Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2.  Lancet. 1988;  2 349-360
    PubMedGoogle Scholar
  • 31 Kjeldsen S E, Kolloch R E, Leonetti G, Mallion J M, Zanchetti A, Elmfeldt D, Warnold I, Hansson L. Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid. The HOT study. Hypertension Optimal Treatment.  J Hypertens. 2000;  18 629-642
    PubMedGoogle Scholar
  • 32 Lewis H D, Davis J W, Archibald D G, Steinke W E, Smitherman T C, Doherty J E, Schnaper H W, LeWinter M M, Linares E, Pouget J M, Sabharwal S C, Chesler E, DeMots H. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study.  N Engl J Med. 1983;  309 396-403
    CrossrefPubMedGoogle Scholar
  • 33 Marshall T. Coronary heart disease prevention: insights from modelling incremental cost effectiveness.  BMJ. 2003;  327 1264
    CrossrefPubMedGoogle Scholar
  • 34 Medical research council's General Practice Research Framework . Thrombosis prevention trial: randomized trial of low intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischemic heart diseases in men at increased risk.  Lancet. 1998;  351 233-241
    CrossrefPubMedGoogle Scholar
  • 35 Niessen L W, Dippel D W, Limburg M. Calculation of costs of stroke, cost effectiveness of stroke units and secondary prevention in patients after a stroke, as recommended by revised CBO practice guideline ‘Stroke’.  Ned Tijdschr Geneeskd. 2000;  144 1959-1964
    PubMedGoogle Scholar
  • 36 Paterson J R, Lawrence J R. Salicylic acid: a link between aspirin, diet and the prevention of colorectal cancer.  QJM. 2001;  94 445-448
    CrossrefPubMedGoogle Scholar
  • 37 Pearson T A, Blair S N, Daniels S R, Eckel R H, Fair J M, Fortmann S P, Franklin B A, Goldstein L B, Greenland P, Grundy S M, Hong Y, Miller N H, Lauer R M, Ockene I S, Sacco R L, Sallis J F, Smith S C, Stone N J, Taubert K A. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee.  Circulation. 2002;  106 388-391
    CrossrefPubMedGoogle Scholar
  • 38 Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, Warlow C, Hafner B, Thompson E, Norton S. et al . Randomised trial of prophylactic daily aspirin in British male doctors.  BMJ. 1988;  296 313-316
    CrossrefPubMedGoogle Scholar
  • 39 Pocock S J, McCormack V, Gueyffier F, Boutitie F, Fagard R H, Boissel J P. A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials.  BMJ. 2001;  323 75-81
    CrossrefPubMedGoogle Scholar
  • 40 Redman A R, Ryan G J. Analysis of trials evaluating combinations of acetylsalicylic acid and dipyridamole in the secondary prevention of stroke.  Clin Ther. 2001;  23 1391-1408
    CrossrefPubMedGoogle Scholar
  • 41 Rexrode K M, Lee I M, Cook N R, Hennekens C H, Buring J E. Baseline characteristics of participants in the Women's Health Study.  J Womens Health Gend Based Med. 2000;  9 19-27
    CrossrefPubMedGoogle Scholar
  • 42 Sanmuganathan P S, Ghahramani P, Jackson P R, Wallis E J, Ramsay L E. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials.  Heart. 2001;  85 265-271
    CrossrefPubMedGoogle Scholar
  • 43 Settipane R A, Constantine H P, Settipane G A. Aspirin intolerance and recurrent urticaria in normal adults and children. Epidemiology and review.  Allergy. 1980;  35 149-154
    PubMedGoogle Scholar
  • 44 Steering Committee of the Physicians' Health Study Research Group . Final report on the aspirin component of the ongoing Physicians' Health Study.  N Engl J Med. 1989;  321 129-135
    CrossrefPubMedGoogle Scholar
  • 45 Stewart W F, Kawas C, Corrada M, Metter E J. Risk of Alzheimer's disease and duration of NSAID use.  Neurology. 1997;  48 626-632
    PubMedGoogle Scholar
  • 46 The SALT Collaborative Group . Swedish Aspirin Low-Dose-trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events.  Lancet. 1991;  338 1345-1349
    CrossrefPubMedGoogle Scholar
  • 47 Thun M J, Henley S J, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues.  J Natl Cancer Inst. 2002;  94 252-266
    PubMedGoogle Scholar
  • 48 Wald N J, Law M R. A strategy to reduce cardiovascular disease by more than 80 %.  BMJ. 2003;  326 1419-1425
    CrossrefPubMedGoogle Scholar
  • 49 Weisman S M, Graham D Y. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events.  Arch Intern Med. 2002;  162 2197-2202
    CrossrefPubMedGoogle Scholar

Dr. Stefan Hensler

Institut für Allgemeinmedizin

Theodor-Stern-Kai 7

60590 Frankfurt

eMail: s.hensler@em.uni-frankfurt.de